Exelixis, Inc. (EXEL) Shares Gap Down on Insider Selling

Insiders own 5.10% of the company's stock. The stock decreased 0.89% or $0.37 on September 22, reaching $41.04. The trade volumes are expected to remain volatile during earnings announcement period, as many investors would reconsider their investment in Exelixis, Inc. based on the results.

Exelixis, Inc. was covered by a number of analysts recently, 1 rated the stock as Buy, 4 rated Hold, 0 rated sell and 0 gave an Underperform. Therefore 80% are positive.

Exelixis, Inc. (EXEL) stock price rose 66.01 percent over the past one year, while increased 17.03 percent during the past 6 months. Exelixis Inc now has $7.19B valuation. (NASDAQ:EXEL) on Wednesday, August 16 with "Hold" rating. The stock presently has a consensus rating of "Buy" and a consensus price target of $27.95. At the time of writing, the First Call consensus price target for the company is $19.25. The rating was maintained by Oppenheimer on Thursday, July 20 with "Hold". Oppenheimer maintained the stock with "Market Perform" rating in Friday, May 5 report. The firm earned "Buy" rating on Sunday, September 10 by Piper Jaffray. (NASDAQ:EXEL). Qs Investors Limited Com reported 0% in Exelixis, Inc. (NASDAQ:EXEL). Macquarie Group, a Australia-based fund reported 140,044 shares. The Farallon Capital Management Llc holds 1.52M shares with $37.31M value, down from 3.52 million last quarter. EXEL's profit will be $20.57M for 87.39 P/E if the $0.07 EPS becomes a reality. Finally, SunTrust Banks, Inc. assumed coverage on shares of Exelixis in a research note on Thursday, July 13th. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases.

Boosts Position in Abbott Laboratories (ABT)
Following the completion of the transaction, the insider now directly owns 105,479 shares in the company, valued at $5,357,278.41. It has underperformed by 0.80% the S&P500.The move comes after 6 months negative chart setup for the $89.71 billion company.

The value of the investment in EXEL went from $1,822,000 to $8,358,000 increasing 358.7% quarter to quarter. Its up 0.36, from 0.97 in 2017Q1.

02/27/2017: Exelixis, Inc. reported Q4 earnings of $0.12, beating consensus estimates of -$0.01. 60 funds opened positions while 70 raised stakes. Rhenman & Partners Asset Management Ab controls 1,050,000 shares with a value of $25,862,000. Bb&T Secs Limited Liability Co reported 0% stake.

Several other research analysts have also weighed in on the company.

Shares now up at $56.29 (SCG) SCANA Corporation Investor Alert: Hagens…
The utilities provider reported $0.85 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.11. The Company, through its subsidiaries, is involved in the generation, transmission, distribution and sale of electricity in SC .

Analysts await ScanSource, Inc. Exelixis, Inc. (NASDAQ:EXEL) has risen 266.48% since September 26, 2016 and is uptrending. (NASDAQ:EXEL). Hbk Investments LP owns 0.02% invested in Exelixis, Inc. (NASDAQ:EXEL). 954 are held by Finance Architects Inc. Cap Fund Management accumulated 0.04% or 177,180 shares. It has the market capitalization of $ billion while 336.42 shares were outstanding. Qci Asset Mgmt New York reported 1,000 shares. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/09/27/exelixis-inc-exel-forecasted-to-post-q3-2017-earnings-of-0-08-per-share.html. Jpmorgan Chase & reported 0% in Exelixis, Inc. Lpl Financial Lc holds 0% or 11,979 shares in its portfolio. (NASDAQ:EXEL). Northern Tru holds 1.27 million shares. Blackrock owns 15.17 million shares for 0.02% of their portfolio. (NASDAQ:EXEL). Renaissance Limited Liability Co invested 0.08% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Vanguard Grp invested in 0.03% or 25.44 million shares.

Since March 27, 2017, it had 0 insider buys, and 7 sales for $13.58 million activity. $711,831 worth of Exelixis, Inc. Another trade for 6,884 shares valued at $144,702 was sold by Hessekiel Jeffrey. 5,150 shares were sold by WYSZOMIERSKI JACK L, worth $111,086. MARCHESI VINCENT T also sold $213,000 worth of Exelixis, Inc. Through this figure traders can analyze that EXEL show whether or not a stock now most active and standing in buying side or sell side. 89,910 shares were sold by Schwab Gisela, worth $2.07 million. More interesting news about Exelixis, Inc. It also upped Twenty (NASDAQ:FOXA) stake by 29,286 shares and now owns 459,783 shares. Shares saw a steep increase in trading volume of 139.45% over the normal average daily volume. It has outperformed by 249.78% the S&P500. During the same quarter a year ago, the firm posted ($0.15) earnings per share. About 1.47M shares traded. Amazon.Com Inc (NASDAQ:AMZN) was raised too.

Analysts have given a mean recommendation of 2.10 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Exelixis had 30 analyst reports since January 19, 2016 according to SRatingsIntel. The firm has "Hold" rating by Zacks given on Monday, August 31. The firm has "Buy" rating by Jefferies given on Tuesday, August 22. The stock of General Dynamics Corporation (NYSE:GD) has "Buy" rating given on Monday, September 18 by Cowen & Co. The rating was initiated by Deutsche Bank on Thursday, November 3 with "Buy". The firm has "Overweight" rating by Barclays Capital given on Monday, November 30. Stifel Nicolaus lowered shares of Exelixis from a "buy" rating to a "hold" rating and set a $22.00 price target for the company.in a report on Tuesday, February 28th.

Nigeria withdraws from 90 worldwide organizations
Muhammadu Buhari speaks the United Nations Sustainable Development Summit at the United Nations General Assembly in NY . Adeosun, a former PricewaterhouseCoopers accountant, described the latest move as "just prudence and value for money".

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Últimas notícias